Last reviewed · How we verify
injection of apomorphine
Apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to improve motor symptoms in Parkinson's disease.
Apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to improve motor symptoms in Parkinson's disease. Used for Parkinson's disease, acute motor fluctuations and 'off' episodes.
At a glance
| Generic name | injection of apomorphine |
|---|---|
| Sponsor | University Hospital, Toulouse |
| Drug class | Dopamine agonist |
| Target | Dopamine receptors (D2, D3) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Apomorphine acts as a non-selective dopamine receptor agonist, primarily binding to D2 and D3 dopamine receptors. In Parkinson's disease, dopamine-producing neurons degenerate, leading to motor dysfunction; apomorphine bypasses this deficit by directly activating dopamine receptors, thereby restoring dopaminergic signaling and alleviating motor symptoms such as tremor, rigidity, and bradykinesia.
Approved indications
- Parkinson's disease, acute motor fluctuations and 'off' episodes
Common side effects
- Nausea
- Yawning
- Injection site reactions
- Dizziness
- Somnolence
- Hypotension
Key clinical trials
- Clinical Trial of Intranasal Delivery of NT-301 (PHASE1)
- Blinking and Yawning in Epilepsy: The Role of Dopamine (NA)
- Motor Network Physiology (NA)
- Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) (PHASE4)
- Apomorphine Effects on Pain in Parkinson's Disease (PHASE2, PHASE3)
- Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease (PHASE2)
- Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease (PHASE3)
- Extended Long-Term Safety Study of KW-6500 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- injection of apomorphine CI brief — competitive landscape report
- injection of apomorphine updates RSS · CI watch RSS
- University Hospital, Toulouse portfolio CI